Assay will predict which patients are best suited to the therapeutic that targets the steroid sulfatase enzyme.

bioMérieux agreed to develop a companion test for Ipsen’s Phase I breast cancer drug candidate. The assay is intended for both the clinical development of the compound as well as a diagnostic test  potentially for future commercialization.

BN 83495 is designed to block the steroid sulfatase enzyme (STS), which is found in hormone-dependent breast cancer in postmenopausal women. bioMérieux will devise a tool to determine the patients best suited to benefit from this STS inhibitor.

The test will be developed on bioMérieux’ NucliSENS EasyQ® molecular diagnostics platform, using the NASBA® amplification technology. The company will will co-fund the project with Ipsen.

Previous articleBioServe and NeoCodex Combine Offerings
Next articlePPG to Divest Fine Chemicals Segment for $65M to ZaCh System